The
American Society of Hematology sent me a few snippets today:
| ||
| Mining the “Gold Rush” of Immunotherapy Clinical Trials As the number of immunotherapy clinical trials grows, so do the obstacles and challenges – including the need to ensure meaningful results. Entering A New Era of Immunotherapy The first approval of a chimeric antigen receptor T-cell therapy marks a shift in the future of the immunotherapy field. | ||
| ||
| The Year in Drug Approvals The excitement over immunotherapy for cancer treatment shows no signs of waning, with several agents approved by the U.S. Food and Drug Administration this year. | ||
| ||
| The Immunotherapy Pipeline Dozens of immunotherapeutic agents are under investigation for the treatment of malignant and non-malignant hematologic conditions. All good stuff... | ||
No comments:
Post a Comment